Drug Profile
BOXR 1030
Alternative Names: BOXR-1030Latest Information Update: 18 Nov 2022
Price :
$50
*
At a glance
- Originator Unum Therapeutics
- Developer SOTIO
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Liver cancer; Lung cancer; Merkel cell carcinoma; Myxoid liposarcoma